Neoleukin Therapeutics, Inc. (NLTX)

Market Cap	32.89M
Revenue (ttm)	n/a
Net Income (ttm)	-57.56M
Shares Out	47.30M
EPS (ttm)	-1.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	209,816
Open	0.690
Previous Close	0.695
Day's Range	0.675 - 0.700
52-Week Range	0.375 - 2.320
Beta	1.19
Analysts	Sell
Price Target	2.04 (+193.4%)
Earnings Date	May 8, 2023

About NLTX

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neole...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2003
• Employees: 77
• Stock Exchange: NASDAQ
• Ticker Symbol: NLTX

Analyst Forecast

According to 10 analysts, the average rating for NLTX stock is "Sell." The 12-month stock price forecast is $2.04, which is an increase of 193.40% from the latest price.

Price Target

$2.04

(193.40% upside)

Analyst Consensus: Sell